Investor Relations

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Sep 30, 2023

mail icon

Sign Up For Email Alerts

Receive updates straight into your inbox

Sign up today

Company Overview

Headquartered in Princeton, NJ, Sonnet BioTherapeutics is a clinical stage biotechnology company with a proprietary platform for innovating biologic drugs of single- or bi-specific mechanisms. Known as FHAB™ (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues. FHAB™ is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies and vaccines.

Investor Contact Information


Sonnet BioTherapeutics, Inc.
100 Overlook Center
Princeton, NJ 08540